The effect of atorvastatin combined with insulin glargine on renal function in patients with early diabetic nephropathy
10.3760/cma.j.issn.1673-4904.2020.02.005
- VernacularTitle: 阿托伐他汀联合甘精胰岛素对早期糖尿病肾病患者肾功能的影响
- Author:
Haiyan SHEN
1
;
Xiangdong LI
1
;
Yi LI
1
;
Ming ZHAO
1
;
Ying ZHAI
1
;
Bohui GUO
1
;
Qingjuan CHEN
2
Author Information
1. Department of Nephrology, Hanzhong 3201 Hospital Affiliated of Xi′an Jiaotong University Medical School, Shaanxi Hanzhong 723000, China
2. Department of Oncology, Xianyang Central Hospital, Shaanxi Xianyang 712000, China
- Publication Type:Journal Article
- Keywords:
Diabetic nephropathy;
Atorvastatin;
Insulin glargine;
Treatment outcome;
Renal function
- From:
Chinese Journal of Postgraduates of Medicine
2020;43(2):118-121
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the effect of atorvastatin combined with insulin glargine on renal function in patients with early diabetic nephropathy.
Methods:From January 2016 to March 2019, 100 patients with early diabetic nephropathy admitted to Hanzhong 3201 Hospital Affiliated with Xi′an Jiaotong University Medical School were selected as subjects. According to the random number table, patients were divided into control group and observation group, with 50 cases in each group. All patients underwent diet control, blood pressure control and symptomatic treatment. Patients in the control group were treated with insulin glargine to control blood glucose. Patients in observation group were given atorvastatin on this basis. After 16 weeks of treatment, the therapeutic effects of the two groups were observed, as well as the change in urinary albumin excretion rate (UAER), serum creatinine (Scr), C-reactive protein (CRP), total cholesterol (TC), and triglyceride (TG). Adverse reactions were observed during treatment in both groups.
Results:After treatment, the levels of UAER, Scr, CRP, TC and TG of the two groups were lower than those before treatment, and the above indexes of the observation group were lower than those of the control group. The difference were statistically significant (P<0.05). During the treatment period, the incidence of adverse reactions in control group and observation group was 4.00%(2/50) and 12.00%(6/50), and there was no significant difference (P>0.05).
Conclusions:Atorvastatin combined with insulin glargine in the treatment of early diabetic nephropathy can effectively reduce the levels of UAER, Scr, CRP, TC and TG, and has good safety.
